证券代码：300642 证券简称：透景生命 公告编号：2023-061 上海透景生命科技股份有限公司 关于第三届董事会第二十一次会议决议的公告 5、本次会议的通知、召开符合《中华人民共和国公司法》（以下简称"《公 司法》"）、《中华人民共和国证券法》、《深圳证券交易所创业板股票上市规 则》（以下简称"《上市规则》"）、《深圳证券交易所上市公司自律监管指引 第 2 号——创业板上市公司规范运作》（以下简称"《规范运作指引》"）、《上 海透景生命科技股份有限公司章程》、《上海透景生命科技股份有限公司董事会 议事规则》的有关规定，合法有效。 二、董事会会议审议情况 1、审议通过《关于公司 2023 年半年度报告及摘要的议案》 报告期内，公司严格按照《公司法》、《上市规则》、《规范运作指引》等 法律、法规及规范性文件运作。公司 2023 年半年度报告及摘要的编制程序符合 法律、行政法规和中国证券监督管理委员会、深圳证券交易所的相关规定，报告 内容真实、准确、完整地反映了公司的实际情况，不存在任何虚假记载、误导性 陈述或者重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或 ...

证券代码：300642 证券简称：透景生命 公告编号：2023-065 上海透景生命科技股份有限公司 关于第三届监事会第十七次会议决议的公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 5、本次会议的通知、召开符合《中华人民共和国公司法》、《深圳证券交易 所创业板股票上市规则》、《深圳证券交易所上市公司自律监管指引第 2 号——创 业板上市公司规范运作》等法律、行政法规、部门规章、规范性文件及《上海透 景生命科技股份有限公司章程》、《上海透景生命科技股份有限公司监事会议事规 则》的相关规定，合法有效。 二、监事会会议审议情况 1、审议通过《关于公司 2023 年半年度报告及摘要的议案》 报告期内，公司严格按照《中华人民共和国公司法》、《深圳证券交易所创业 板股票上市规则》、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上 市公司规范运作》等法律、法规及规范性文件运作。经审核，监事会认为董事会 编制和审核公司 2023 年半年度报告及其摘要的程序符合法律、行政法规和中国 证监会的规定，报告内容真实、准确、完整地反映了公司的实际情况，不存在任 何虚假 ...

证券代码：300642 证券简称：透景生命 公告编号：2023-060 上海透景生命科技股份有限公司 关于取得泰国医疗器械注册认证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 | | PGI (CLIA) | 本产品供医疗机构用于体外定量检测人血清中胃蛋白酶原Ⅰ （pepsinogenⅠ，PGⅠ）的浓度，作辅助诊断用，不用于胃癌 | | --- | --- | --- | | 8 | 中文名：胃蛋白酶原Ⅰ测定试剂盒（化 | 的辅助诊断。胃蛋白酶原Ⅰ/Ⅱ检测试剂盒用于检测血清或者 | | | 学发光免疫分析法） | 血浆中的胃蛋白酶原Ⅰ/Ⅱ的含量，具有简便、快速的优势， | | | | 避免了X-射线对人体的侵害和胃镜的不便。 | | | | 本产品供医疗机构用于体外定量检测人血清中胃蛋白酶原Ⅱ | | | PGII (CLIA) | （pepsinogen Ⅱ，PGⅡ）的浓度，作辅助诊断用，不用于胃 | | 9 | 中文名：胃蛋白酶原Ⅱ测定试剂盒（化 | 癌的辅助诊断。胃蛋白酶原Ⅰ/Ⅱ检测试剂盒用于检测血清或 | | | 学发光免疫分析法） | 者血 ...

Financial Performance - The company's revenue for Q1 2023 was ¥121,844,833.48, a decrease of 16.03% compared to ¥145,099,766.40 in the same period last year[3] - Net profit attributable to shareholders increased by 111.17% to ¥11,129,200.78 from ¥5,270,134.33 year-on-year[3] - The net profit excluding non-recurring gains and losses rose by 207.79% to ¥9,434,141.08 from ¥3,065,114.09 in the previous year[3] - Basic earnings per share increased by 110.80% to ¥0.0683 from ¥0.0324 in the same period last year[3] - Total operating revenue for Q1 2023 was CNY 121,844,833.48, a decrease of 16.04% compared to CNY 145,099,766.40 in the same period last year[21] - Net profit for Q1 2023 reached CNY 10,465,770.51, an increase of 99.00% compared to CNY 5,242,502.79 in Q1 2022[23] - The total comprehensive income attributable to the parent company reached ¥11,129,200.78, a significant increase from ¥5,270,134.33 in the previous period, representing a growth of approximately 111.5%[24] - Basic earnings per share increased to ¥0.0683 from ¥0.0324, reflecting a growth of 111.1% year-over-year[24] Cash Flow and Assets - The net cash flow from operating activities was negative at -¥2,017,596.63, a decline of 102.90% compared to ¥69,670,388.41 in the previous year[3] - Cash inflow from operating activities totaled ¥130,566,248.79, down 32.9% from ¥194,746,627.61 in the prior period[26] - Cash outflow from operating activities increased to ¥132,583,845.42, compared to ¥125,076,239.20 in the previous period, marking an increase of 6.4%[26] - Cash flow from investing activities generated a net inflow of ¥9,176,923.09, down from ¥58,012,186.31 in the previous period, indicating a decrease of 84.2%[27] - The company reported cash and cash equivalents at the end of the period amounting to ¥263,674,946.15, down from ¥307,162,432.92 in the previous period, a decrease of 14.1%[27] - The company's cash and cash equivalents increased to CNY 263,934,030.25 from CNY 243,484,642.21 at the beginning of the year, reflecting a growth of 8.99%[18] - Total assets at the end of Q1 2023 were ¥1,648,539,962.01, a decrease of 0.97% from ¥1,664,722,687.00 at the end of the previous year[3] - Total liabilities decreased to CNY 153,798,531.52 from CNY 184,073,131.32, a reduction of 16.43%[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,102[11] - The largest shareholder, Yao Jian'er, holds 19.93% of shares, totaling 32,753,700 shares, with 24,565,275 shares pledged[11] - Lingfei Group Limited holds 7.32% of shares, totaling 12,035,800 shares, with 8,580,000 shares pledged[11] - The total number of shares held by the top ten unrestricted shareholders includes UBS AG with 5.03% (8,271,877 shares) and Merrill Lynch International with 3.72% (6,122,677 shares)[12] - The total number of shares held by the top ten shareholders represents a significant concentration of ownership, with the top three shareholders holding over 32% combined[11] Stock Incentive Plan - The company completed the grant and registration of 1.61 million restricted shares and 4.78 million stock options under the 2023 stock option and restricted stock incentive plan[16] - The total number of restricted shares at the end of the period is 26,674,775 shares, with no shares released during the reporting period[15] - The company adjusted performance assessment targets in the stock incentive plan to enhance operational feasibility and challenge[16] - The company has a total of 445,500 other restricted shares, with 1,530,000 shares added during the reporting period[15] - The company’s core team stability and employee motivation are prioritized through the revised stock incentive plans[16] Tax and Other Financial Metrics - The company experienced a 41.57% decrease in taxes and surcharges, amounting to ¥1,425,628.71, due to reduced revenue and profit[9] - The company reported an investment income of ¥8,555,652.76, a significant increase of 253.27% compared to ¥2,421,856.89 in the previous year[9] - The net cash flow from financing activities increased by 318.13% to ¥14,208,736.62, primarily due to received equity incentive subscription payments[9] - The company experienced a foreign exchange loss of ¥918,675.04, compared to a loss of ¥218,346.10 in the previous period[27]

Financial Performance - The company's operating revenue for 2022 was ¥715,970,892.34, an increase of 9.38% compared to ¥654,588,606.63 in 2021[21]. - The net profit attributable to shareholders for 2022 was ¥124,759,250.34, a decrease of 22.55% from ¥161,082,764.14 in 2021[21]. - The net cash flow from operating activities increased by 99.39% to ¥164,719,466.16 in 2022, compared to ¥82,613,509.16 in 2021[21]. - The total assets at the end of 2022 were ¥1,664,722,687.00, reflecting an 11.07% increase from ¥1,498,842,208.60 at the end of 2021[21]. - The company reported a basic earnings per share of ¥0.767 for 2022, down 22.29% from ¥0.987 in 2021[21]. - The weighted average return on equity for 2022 was 8.77%, a decrease of 3.35% from 12.12% in 2021[21]. - The overall gross margin for the company was 57.04%, down 9.81 percentage points compared to the same period last year, primarily due to the lower gross margin of instruments at 15.96% compared to reagents at 70.64%[68]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the year, representing a growth of 25% compared to the previous year[112]. Market and Product Development - The company plans to continue expanding its market presence and investing in new technologies to enhance its product offerings[30]. - The company has obtained a total of 326 domestic medical device registration and filing certificates, including 232 for Class II and III medical devices[40]. - The company has developed 21 tumor marker detection products, making it one of the most comprehensive companies in this field in China[40]. - The company is actively exploring overseas markets and has established stable partnerships with overseas distributors[37]. - The company has developed the first domestic lung cancer methylation detection product, enhancing its product portfolio in molecular diagnostics[39]. - The company has developed a biochemical immunocompatible assembly line that can integrate mainstream chemiluminescence and flow fluorescence detection instruments, addressing automation needs in testing[59]. - The company is focused on expanding its product offerings, with a total of 46 registered products aimed at different clinical applications, enhancing its market presence[83]. Research and Development - The company maintains a research and development investment ratio of approximately 10% of its revenue, focusing on various fields including autoimmune diseases and cancer[53]. - The company has a dedicated R&D team of 123 personnel, accounting for 17.32% of total staff, ensuring a strong focus on innovation and product development[60]. - The company is developing multiple projects in flow cytometry and chemiluminescence detection, aiming to enhance its product offerings in the future[77]. - The company is actively involved in the development of new diagnostic technologies, including assays for thyroid-related antibodies and vitamin D levels[82]. - The company has implemented a rapid production model to meet the uncertain demands of new customers, adjusting production plans based on inventory levels[48]. Risk Management - The company has outlined potential risks and corresponding countermeasures in the management discussion section of the report[5]. - The company acknowledges the risk of product quality issues that could adversely affect its operations, finances, and reputation if significant quality problems arise[107]. - The company recognizes the risk of declining product gross margins due to intensified competition and rising costs, and plans to optimize production processes to mitigate this risk[110]. - The company faces risks related to industry policy changes, which could impact customer structure, pricing, and distributor management due to ongoing healthcare reforms[106]. Corporate Governance - The company emphasizes the importance of accurate financial reporting and has ensured that all board members attended the meeting to review the annual report[5]. - The company has established independent decision-making and supervisory bodies, including a board of directors and a supervisory board, ensuring operational independence[120]. - The company has a clear and complete asset structure, with independent production facilities and necessary technology[119]. - The company has established a governance structure that includes independent directors and a compensation committee to ensure transparency and accountability[132]. - The company has maintained compliance with all regulatory requirements, ensuring no significant discrepancies in governance practices[118]. Shareholder Relations and Profit Distribution - The company reported a cash dividend of 2.00 RMB per 10 shares for all shareholders, based on a total of 164,381,741 shares[5]. - The total cash dividend distributed for the reporting period was RMB 40,716,774.75, based on a distribution of RMB 2.50 per 10 shares[158]. - The company plans to distribute cash dividends annually, with a minimum of 20% of the distributable profit attributable to shareholders being allocated as cash dividends each year[151]. - The company has established a mechanism for independent directors to provide opinions on the profit distribution plan, ensuring transparency and accountability[154]. Environmental Responsibility - The company adheres to pollution prevention and environmental protection policies, focusing on clean production and energy conservation[175]. - The company has completed ISO14001 environmental management system certification and ISO45001 occupational health and safety management system certification, emphasizing its commitment to environmental protection and energy conservation[183]. - The company has implemented measures to manage solid waste, including hazardous waste, through qualified disposal services[176]. - The company has initiated an environmental carbon reduction action plan, collecting a total of 6 projects aimed at promoting environmental and carbon reduction initiatives[183]. Employee Management - The company has established a comprehensive compensation and welfare system, including social security, medical insurance, and housing funds, to protect employee rights[185]. - The total remuneration paid to directors, supervisors, and senior management during the reporting period amounted to 6.2861 million yuan[132]. - The company emphasizes a multi-level and diversified salary model, adhering to national laws and internal regulations[146]. - The training management system includes onboarding training for new employees and targeted training for different management levels, adjusting annually based on business needs[147].

为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于本次业绩 说明会召开前五个交易日内访问"互动易"平台首页右侧点击"提问预征集"， 进入问题征集专题页面进行提问。公司将在 2022 年度业绩说明会上对投资者普 遍关注的问题进行回答。欢迎广大投资者积极参与本次网上业绩说明会。 特此公告。 上海透景生命科技股份有限公司 上海透景生命科技股份有限公司 关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 上海透景生命科技股份有限公司（以下简称"公司"）于 2023 年 4 月 22 日 披露《2022 年年度报告》及其摘要。为了更好地与广大投资者进行交流，使投 资者能够进一步了解公司 2022 年度经营情况，公司定于 2023 年 5 月 5 日（星期 五）15:00—17:00 在深圳证券交易所"互动易"平台举办 2022 年度业绩说明会。 本次年度业绩说明会将采取网络远程的方式举行，投资者可登录通过"互动易" 平台（http://irm. ...

证券代码：300642 证券简称：透景生命 上海透景生命科技股份有限公司 投资者关系活动记录表 编号：IR-2017001 | --- | --- | --- | --- | |-------------------------|----------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------| | | | | | | | | | | | | þ | 特定对象调研 □媒体采访 □分析师 ...

证券代码：300642 证券简称：透景生命 上海透景生命科技股份有限公司 投资者关系活动记录表 编号：IR-2017002 | --- | --- | --- | |-------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系 \n活动类别 | þ \n□ 现场参观 □其他： | 特定对象调研 □媒体采访 □分析师会议 \n□新闻发布会 □业绩说明会 □路演活动 | | 参与单位名称 及人员姓名 | | 天风证券郑薇，博时基金葛晨、陈西铭、尹哲，农银汇理陈卫 ...

证券代码：300642 证券简称：透景生命 上海透景生命科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |---------------------|--------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系 活动类别 | þ \n□新闻发布会 □业绩说明会 □路演活动 | 编号： IR-2018001 \n特定对象调研 □媒体采访 □分析师会议 | | | □ 现场参观 □其他： | | | 参与单位名称 | | 中信建投证券程培、 翁延帆，交银施罗德基金刘牧，财通自营叶铮 ，幂方资 本卢玮，富舜资产李根林，朱雀投资张皓，光证资管曾炳祥，格林基金范坤 | | 及人员姓名 | 君安证券杨盼等。 | 祥，东海基金杨莹，德邦资管 ...